FOSUN PHARMA (600196.SH) has announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval from the National Medical Products Administration to conduct clinical trials of FXS0683 tablets for hematologic malignancies. The subsidiary plans to initiate a Phase I clinical study of FXS0683 in China once conditions are met. FXS0683 is an orally administered small-molecule innovative drug independently developed by the group, functioning as a potent and highly selective new-generation Bcl-2 inhibitor intended for the treatment of hematologic malignancies. By targeting and inhibiting the activity of both wild-type and mutant Bcl-2 proteins, FXS0683 promotes apoptosis in tumor cells, thereby inhibiting tumor cell proliferation and tumor tissue growth.